FX.co ★ Roche To Acquire Poseida For Up To $1.5 Bln

Roche Holding AG, a prominent Swiss healthcare company, has announced on Tuesday a definitive agreement to acquire Poseida Therapeutics, Inc. for $9 per share in cash upon closing. This transaction is projected to conclude in the first quarter of 2025.

Under the terms of the agreement, Roche will initiate a tender offer to purchase Poseida's outstanding shares at $9.00 per share in cash at closing. Additionally, shareholders will receive a contingent value right (CVR) that includes the possibility of milestone payments up to an additional $4.00 per share in cash.

The acquisition initially values Poseida at approximately $1 billion, with the potential to reach a total value of $1.5 billion. The offer represents a 215% premium compared to Poseida's share price as of November 25.

Roche has stated that this acquisition aligns with its strategic goals of advancing new and innovative treatments in the fields of oncology, immunology, and neurology, positioning itself at the forefront of allogeneic cell therapies.

The acquisition will also strengthen an existing collaboration between Roche and Poseida, particularly in the development of CAR-T cell therapies for blood cancers, a partnership that commenced in 2022.

On the day prior to this announcement, Poseida’s shares closed at $2.86 on the Nasdaq, reflecting a 4.76% increase. Following the announcement, the shares experienced an additional 11.19% rise in extended trading, reaching $3.18.